A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.

• প্রধান লেখক: Mohamed Osman (লেখক), Anoop Mistry (লেখক), Ada Keding (লেখক), Rhian Gabe (লেখক), Elizabeth Cook (লেখক), Sarah Forrester (লেখক), Rebecca Wiggins (লেখক), Stefania Di Marco (লেখক), Stefano Colloca (লেখক), Loredana Siani (লেখক), Riccardo Cortese (লেখক), Deborah F Smith (লেখক), Toni Aebischer (লেখক), Paul M Kaye (লেখক), Charles J Lacey (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Public Library of Science (PLoS), 2017-05-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Visceral leishmaniasis (VL or kala azar) is the most serious form of human leishmaniasis, responsible for over 20,000 deaths annually, and post kala azar dermal leishmaniasis (PKDL) is a stigmatizing skin condition that often occurs in patients after successful treatment for VL. Lack of effective or...